Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT01585805
Show Display Options
Rank Status Study
1 Recruiting Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Pancreatic Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: Veliparib;   Drug: Gemcitabine Hydrochloride;   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis

Indicates status has not been verified in more than two years